Trials / Completed
CompletedNCT00061126
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Abgenix · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body. Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABX-EGF |
Timeline
- Start date
- 2003-04-01
- First posted
- 2003-05-22
- Last updated
- 2005-06-24
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00061126. Inclusion in this directory is not an endorsement.